Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Eur J Cancer

Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS

doi: 10.1016/j.ejca.2026.116744

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

ELCC 2026

Lung, Respiratory and Thoracic Cancer

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

ELCC 2026

Lung, Respiratory and Thoracic Cancer

PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)

J Thorac Oncol

Kenmotsu H, Saito Y, Ninomiya K, Uematsu S, Akdemir B, Fukui A, Koto R, Fujiwara M, Iwao C, Kitagawa H, Yoshino I, Gemma A, Mitsudomi T, Yamamoto N

doi: 10.1016/j.jtho.2025.08.010

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Lung, Respiratory and Thoracic Cancer

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis

Lung Cancer

Alexander M, Itchins M, Felthun J, Nagrial A, Brown LJ, O'Byrne K, Mersiades AJ, Hughes BGM, Warburton L, Kong BY, Moore M, Blinman P, Bowyer S, Clay T, Spelman T, Pavlakis N, Solomon BJ, Kao S

doi: 10.1016/j.lungcan.2025.108854

Related content

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis